Buy Nexavar : Sorafenib 200 Mg Tablets 60’S Online

Description

Overview: Nexavar is a medication manufactured by Bayer Pharmaceuticals Pvt. Ltd. containing the active substance Sorafenib. It is a multi-kinase inhibitor used in the treatment of various types of cancer, including advanced hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Active Substance:

• Sorafenib: Nexavar contains Sorafenib, which is a multi-kinase inhibitor that targets multiple protein kinases involved in tumor cell proliferation, angiogenesis (formation of new blood vessels), and tumor progression. Sorafenib inhibits the activity of receptor tyrosine kinases (RTKs) such as vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and Raf kinases, thereby disrupting signaling pathways that promote tumor growth and survival.

Indications: Nexavar (Sorafenib) 200 mg Tablets are indicated for:

1. Advanced Hepatocellular Carcinoma (HCC): It is used for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or advanced HCC that has progressed on or is not amenable to surgical or locoregional therapies.
2. Advanced Renal Cell Carcinoma (RCC): Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior systemic therapy.
3. Locally Recurrent or Metastatic, Progressive Differentiated Thyroid Carcinoma (DTC): It is used for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Mechanism of Action: Sorafenib exerts its therapeutic effects by inhibiting the activity of multiple protein kinases involved in tumor cell proliferation, angiogenesis, and tumor progression. By targeting receptor tyrosine kinases (RTKs) such as VEGFRs, PDGFRs, and Raf kinases, Sorafenib interferes with signaling pathways that promote tumor growth, invasion, and metastasis. This leads to inhibition of tumor cell proliferation, induction of apoptosis (programmed cell death), and suppression of tumor angiogenesis, ultimately resulting in decreased tumor growth and progression.

Dosage and Administration: The dosage of Nexavar (Sorafenib) 200 mg Tablets is determined by the prescribing healthcare provider based on the patient’s medical condition, body weight, and response to treatment. It is typically administered orally, with or without food, twice daily (morning and evening), at approximately 12-hour intervals. The tablets should be swallowed whole with a glass of water and should not be crushed, chewed, or split. Treatment with Nexavar may continue as long as the patient derives clinical benefit and tolerates the medication.

Potential Side Effects: Common side effects associated with Nexavar may include:

• Diarrhea
• Fatigue or weakness
• Hand-foot skin reaction (palmar-plantar erythrodysesthesia)
• Hypertension (high blood pressure)
• Rash or skin reactions
• Nausea or vomiting
• Decreased appetite
• Abdominal pain

Precautions:

• Nexavar should be used with caution in patients with a history of cardiac disease, bleeding disorders, or hypertension.
• Patients should be monitored regularly for signs of adverse reactions, including hypertension, hand-foot skin reaction, and hepatotoxicity.
• Nexavar may interact with other medications, including CYP3A4 inducers or inhibitors, increasing the risk of adverse effects or altering plasma concentrations of Sorafenib.

In conclusion, Nexavar (Sorafenib) 200 mg Tablets manufactured by Bayer Pharmaceuticals Pvt. Ltd. are used in the treatment of advanced HCC, RCC, and progressive DTC that is refractory to radioactive iodine treatment. By inhibiting multiple protein kinases involved in tumor growth and angiogenesis, Sorafenib offers a targeted approach to cancer therapy. However, it may cause side effects and should be used under medical supervision.